✳️ Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis.
▶️ Conclusion: Our results suggest that both agents are equally effective at controlling symptoms within two weeks of the first infusion, with a small number of patients receiving either having recurrent disease. The two drugs have a comparable safety profile with primarily mild AEs occurring. Our preliminary findings suggest that both drugs can be used effectively in first-line treatment of IMDC, but further data is necessary to ascertain long-term outcomes.
Open Access
▶️ Conclusion: Our results suggest that both agents are equally effective at controlling symptoms within two weeks of the first infusion, with a small number of patients receiving either having recurrent disease. The two drugs have a comparable safety profile with primarily mild AEs occurring. Our preliminary findings suggest that both drugs can be used effectively in first-line treatment of IMDC, but further data is necessary to ascertain long-term outcomes.
Open Access
Management of Hepatitis B 2026 ANNALS of Hepatology.pdf
968.9 KB
ALEH position statement on the management of hepatitis B virus
infection.
infection.
Annals Of Hepatology Jan.2026
🔥3❤1
IMG_6444.JPG
236.5 KB
ACG Clinical Guideline: Diagnosis and Management of Gastric Premalignant Conditions
British_Society_of_Gastroenterology_guidelines_on_colorectal_surveillance.pdf
5.1 MB
British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease
BSG March 2026